ReviewCells2026
1,8-Cineole (Eucalyptol) in Neurodegeneration: From Pharmacological Mechanisms to Therapeutic Applications.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neurodegenerative diseases represent an enormous global burden, and due to the lack of effective therapies, the number of affected individuals continues to rise, placing a significant pressure on patients and their families. Phytochemicals such as terpenes are a group of compounds that have the potential to provide long-term neuroprotective effects by targeting multiple pathobiological pathways and supporting the brain's natural defense mechanisms. 1,8-cineole (eucalyptol) is a monoterpene known for its anti-inflammatory and antioxidant properties, mainly utilized in the respiratory system. However, due to its ability to cross the blood-brain barrier, beneficial effects have been observed in the central nervous system. Here we examine the pharmacological mechanisms and neuroprotective potential of 1,8-cineole in the nervous tissue. Studies have shown that 1,8-cineole has the potential to suppress neuroinflammation and reduce glial activation, activate antioxidant defense mechanisms and scavenge reactive oxygen species. Additionally, 1,8-cineole has been shown to modulate central neurotransmission and synaptic plasticity, inhibit apoptotic neuronal death and regulate ion channels involved in pain modulation. This review aims to examine the therapeutic potential of 1,8-cineole in the most prevalent neurodegenerative diseases in the population, such as Alzheimer's and Parkinson's diseases, as well as brain injuries, including ischemic stroke and traumatic brain injury, which may lead to neurodegeneration. We also explore the potential benefits of 1,8-cineole for anxiety and depression, which occur as early symptoms or common complications of neurodegenerative diseases. Given the need for novel therapeutic approaches, combination therapies that utilize the therapeutic potential of phytochemicals, such as 1,8-cineole, may enable more effective targeting of the multiple, interconnected pathobiological processes underlying neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.